Kurma Partners

Brink Therapeutics is a biotechnology research firm specializing in cell therapy development. It focuses on using reprogrammed recombinases, a type of enzyme that can alter DNA, to create innovative therapies. The company's proprietary technology, designed for in-vivo cell and gene therapy, mimics natural selection to enhance proteins and accelerate testing of recombinases. This enables researchers to develop more efficient and controlled therapies for complex diseases, including cancer and inherited conditions.

Germitec is a healthcare company focused on the design and commercialization of ultraviolet light disinfection systems aimed at enhancing hospital hygiene. By specializing in high-level disinfection using UV-C technology, Germitec provides solutions for reprocessing non-lumen medical devices. The company's innovations are intended to simplify the responsibilities of healthcare professionals, improving safety and efficiency while effectively reducing the risk of cross-infection in clinical settings. Through its advanced disinfection systems, Germitec seeks to transform clinical practices and contribute to better healthcare outcomes.

Raidium is a Medtech company specializing in radiology-augmented technology. It is developing the first radiological foundation model, often referred to as the "GPT-4" of radiology, to simplify precision medicine. Raidium's deep learning algorithms analyze medical imaging data, providing AI-assisted diagnoses to radiologists via an integrated console. This enables earlier detection and management of serious conditions like cancer and cardiovascular diseases.

Shorla Pharma Limited is an Irish specialty pharmaceutical company focused on developing and manufacturing oncology drugs for orphan and pediatric cancers. Established in 2017 and headquartered in Clonmel, Ireland, with an additional office in New York, the company aims to provide accessible and affordable life-saving treatments. Its product portfolio includes SH-111, a sterile injectable solution designed to treat T-cell leukemia in both pediatric and adult patients, as well as SH-105, another oncology drug. Shorla Pharma is dedicated to enhancing patient care and making a significant clinical impact through its innovative therapies.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly focusing on acute decompensated heart failure. The company aims to address unmet medical needs by creating first-in-class drugs that enhance the understanding of disease biology among medical professionals. In addition to heart failure, Corteria also explores treatments for related conditions, such as sarcopenia and obesity, to improve patient outcomes and provide effective solutions for complex health issues. Through its research and development efforts, Corteria Pharmaceuticals seeks to transform the landscape of heart failure treatment.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Ermium Therapeutics is a Paris-based biotechnology company developing therapies for autoimmune and inflammatory diseases. It focuses on a G protein-coupled receptor pathway centered on CXCR4, described as a master regulator of inflammation that modulates interferon production by plasmacytoid dendritic cells, with a platform aimed at controlling inflammatory responses. The company builds on intellectual property licensed from CNRS and University Paris Descartes through an arrangement with Erganeo, supporting its maturation from academic research. Founded in 2019, Ermium Therapeutics aims to translate its discovery into clinically relevant treatments for autoimmune diseases.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

Germitec is a healthcare company focused on the design and commercialization of ultraviolet light disinfection systems aimed at enhancing hospital hygiene. By specializing in high-level disinfection using UV-C technology, Germitec provides solutions for reprocessing non-lumen medical devices. The company's innovations are intended to simplify the responsibilities of healthcare professionals, improving safety and efficiency while effectively reducing the risk of cross-infection in clinical settings. Through its advanced disinfection systems, Germitec seeks to transform clinical practices and contribute to better healthcare outcomes.

FeetMe is a digital health company that develops a platform and connected footwear insoles for gait and movement analysis in-clinic and real-world settings. The technology combines pressure sensors, motion data, and learning algorithms to provide real-time gait and posture insights and digital biomarkers to support clinical research and improve care for patients with movement disorders and mobility constraints. These insights enable clinicians to monitor disease progression, tailor treatments, and optimize medication use by assessing mobility capacity and tracking changes over time.

ARMGO Pharma is a biopharmaceutical company focused on developing small-molecule therapeutics to treat debilitating cardiac, skeletal muscle, and neurological disorders. It develops Rycals, calcium release channel stabilizers that act on the ryanodine receptor/calcium release channel on the sarcoplasmic/endoplasmic reticulum to address chronic heart failure, arrhythmias, muscle disorders, cognitive disorders, and related conditions. The company was founded in 2004 and is based in Tarrytown, New York, with an additional office in New York, New York.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly focusing on acute decompensated heart failure. The company aims to address unmet medical needs by creating first-in-class drugs that enhance the understanding of disease biology among medical professionals. In addition to heart failure, Corteria also explores treatments for related conditions, such as sarcopenia and obesity, to improve patient outcomes and provide effective solutions for complex health issues. Through its research and development efforts, Corteria Pharmaceuticals seeks to transform the landscape of heart failure treatment.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Argobio is a startup studio dedicated to cultivating innovative biotechnology solutions. It sources early-stage projects from leading European academic institutions focusing on rare diseases, neurological disorders, oncology, immunology, and platform technologies for therapeutic products.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its unique T-win technology platform, the company creates first-in-class immune-modulating cancer vaccines that aim to activate T cells specific to immune-suppressive molecules. This approach allows for the simultaneous targeting and disruption of multiple pathways that tumors exploit to evade the immune response. IO Biotech has demonstrated a strong capability in advancing its preclinical and clinical candidates, with its two leading compounds targeting IDO and PD-L1 currently in clinical development, while several others are in the preclinical phase.

Corlieve Therapeutics SAS is a biotechnology company based in Paris, France, dedicated to developing innovative therapeutic options for patients suffering from severe neurological disorders. Founded in 2019, the company focuses on a lead project that targets aberrantly expressed kainate receptors in the hippocampus of patients with temporal lobe epilepsy (TLE) through a gene therapy approach. This novel AAV gene therapy program aims to address refractory TLE, leveraging scientific research from notable institutions such as INSERM, CNRS, Aix Marseille University, and the University of Bordeaux. By advancing its therapeutic strategies, Corlieve Therapeutics seeks to enhance the quality of life for individuals impacted by these challenging conditions.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Founded in 2014, Sensome develops innovative micro-sensor technology that transforms invasive vascular medical devices into connected healthcare devices. Its AI-powered sensors detect the composition of blockages during stroke treatment, initially focusing on neurovascular indications before expanding to peripheral vascular and cardiovascular applications.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

Tacalyx GmbH is an oncology company based in Berlin, Germany, dedicated to the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies for cancer treatment. As a spin-off from the Max-Planck-Institute of Colloids and Interfaces, the company leverages advanced carbohydrate synthesis technology to produce highly pure TACA structures. These structures serve as novel targets for cancer therapies, addressing the tumor-specific expression of TACAs that results from aberrant glycosylation, which is linked to cancer progression, including metastasis and immune system suppression. Tacalyx aims to develop innovative therapeutics that enhance the effectiveness of immunotherapies by triggering robust anti-cancer responses through the synthesis and identification of antibodies targeting these carbohydrate antigens.

FeetMe is a digital health company that develops a platform and connected footwear insoles for gait and movement analysis in-clinic and real-world settings. The technology combines pressure sensors, motion data, and learning algorithms to provide real-time gait and posture insights and digital biomarkers to support clinical research and improve care for patients with movement disorders and mobility constraints. These insights enable clinicians to monitor disease progression, tailor treatments, and optimize medication use by assessing mobility capacity and tracking changes over time.

Ermium Therapeutics is a Paris-based biotechnology company developing therapies for autoimmune and inflammatory diseases. It focuses on a G protein-coupled receptor pathway centered on CXCR4, described as a master regulator of inflammation that modulates interferon production by plasmacytoid dendritic cells, with a platform aimed at controlling inflammatory responses. The company builds on intellectual property licensed from CNRS and University Paris Descartes through an arrangement with Erganeo, supporting its maturation from academic research. Founded in 2019, Ermium Therapeutics aims to translate its discovery into clinically relevant treatments for autoimmune diseases.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Asarina Pharma AB is a Swedish biotechnology company dedicated to developing innovative treatments for premenstrual dysphoric disorder (PMDD) and other conditions related to hormonal fluctuations. The company's primary focus is on Sepranolone, a therapeutic agent designed to address the challenges associated with PMDD. In addition to Sepranolone, Asarina is advancing a second-generation oral compound in preclinical development aimed at PMDD. The company's research is rooted in over 40 years of studies on Allopregnanolone-related neurological disorders, and it is also working on a new family of compounds known as GAMSA (GABA-A Modulating Steroid Antagonists). These efforts aim to create effective and safe treatments for various neuroendocrinological conditions that remain inadequately addressed in the current medical landscape.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

Founded in 2014, Sensome develops innovative micro-sensor technology that transforms invasive vascular medical devices into connected healthcare devices. Its AI-powered sensors detect the composition of blockages during stroke treatment, initially focusing on neurovascular indications before expanding to peripheral vascular and cardiovascular applications.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

FeetMe is a digital health company that develops a platform and connected footwear insoles for gait and movement analysis in-clinic and real-world settings. The technology combines pressure sensors, motion data, and learning algorithms to provide real-time gait and posture insights and digital biomarkers to support clinical research and improve care for patients with movement disorders and mobility constraints. These insights enable clinicians to monitor disease progression, tailor treatments, and optimize medication use by assessing mobility capacity and tracking changes over time.

Founded in 2014, Sensome develops innovative micro-sensor technology that transforms invasive vascular medical devices into connected healthcare devices. Its AI-powered sensors detect the composition of blockages during stroke treatment, initially focusing on neurovascular indications before expanding to peripheral vascular and cardiovascular applications.

Vivet Therapeutics SAS is a biotechnology company based in Paris, France, focused on the research, development, and commercialization of gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016, the company utilizes a liver-tropic adeno-associated virus (AAV) to deliver therapeutic genes directly to hepatocytes, aiming to correct genetic disorders at the source. Vivet is particularly engaged in developing innovative solutions for conditions such as Wilson disease, Progressive Familial Intrahepatic Cholestasis (PFIC), and Citrullinemia Type I (CTLN1). To enhance its gene therapy approaches, Vivet collaborates with the Fundación para la Investigación Médica Aplicada at the Centro de Investigación Médica Aplicada, focusing on optimizing AAV vectors for targeted liver delivery and ensuring long-term expression of therapeutic genes.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

OxThera AB is a biopharmaceutical company focused on developing innovative therapies for the treatment of primary and secondary hyperoxaluria, a condition that can lead to kidney damage. Founded in 2005 and headquartered in Stockholm, Sweden, with an additional facility in Knoxville, Tennessee, OxThera specializes in products that utilize bacteria and enzymes to manage oxalate levels in the body. Its leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced endogenously, and Oxazyme, a non-systemic oral drug made from recombinant oxalate decarboxylase aimed at treating dietary hyperoxaluria and preventing kidney stones. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in addressing unmet medical needs in this therapeutic area. The company holds worldwide patents for its unique compositions and treatment methods targeting hyperoxaluria.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company focuses on creating innovative therapeutics, notably developing DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 for the treatment of Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is expanding its research portfolio to address other orphan disorders, including a program targeting hereditary spastic paraplegias caused by specific genetic mutations. Through its commitment to rare disease drug development, Dynacure seeks to provide effective treatment options for patients with limited therapeutic alternatives.

Asarina Pharma AB is a Swedish biotechnology company dedicated to developing innovative treatments for premenstrual dysphoric disorder (PMDD) and other conditions related to hormonal fluctuations. The company's primary focus is on Sepranolone, a therapeutic agent designed to address the challenges associated with PMDD. In addition to Sepranolone, Asarina is advancing a second-generation oral compound in preclinical development aimed at PMDD. The company's research is rooted in over 40 years of studies on Allopregnanolone-related neurological disorders, and it is also working on a new family of compounds known as GAMSA (GABA-A Modulating Steroid Antagonists). These efforts aim to create effective and safe treatments for various neuroendocrinological conditions that remain inadequately addressed in the current medical landscape.

STAT-Diagnostica is a company dedicated to the development of near-patient testing products aimed at enhancing healthcare delivery. It specializes in creating point-of-care diagnostic devices designed for rapid turnaround applications and critical care environments. The company's flagship product, DiagCORE, is a portable multi-analyte instrument that supports both molecular and immunoassay testing across various clinical settings. By integrating multiple testing techniques into a single device, STAT-Diagnostica enables healthcare professionals to streamline patient care and improve diagnostic efficiency.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

BliNK Biomedical is a biotechnology company focused on discovery and development of monoclonal antibody therapeutics, with an emphasis on immuno-oncology and cancer. It uses a B-cell technology platform to select and isolate antibody-producing cells from multiple species, including humans, mice, rabbits, and dogs, enabling deep mining for difficult targets and the identification of novel antibodies. Its programs aim to create first- or best-in-class antibody-based therapies, including lead candidates that target immune checkpoints to reprogram the tumor immune environment and render cancers susceptible to the body's immune response. The company was founded in 2014 and is based in Lyon, France.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

OxThera AB is a biopharmaceutical company focused on developing innovative therapies for the treatment of primary and secondary hyperoxaluria, a condition that can lead to kidney damage. Founded in 2005 and headquartered in Stockholm, Sweden, with an additional facility in Knoxville, Tennessee, OxThera specializes in products that utilize bacteria and enzymes to manage oxalate levels in the body. Its leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced endogenously, and Oxazyme, a non-systemic oral drug made from recombinant oxalate decarboxylase aimed at treating dietary hyperoxaluria and preventing kidney stones. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in addressing unmet medical needs in this therapeutic area. The company holds worldwide patents for its unique compositions and treatment methods targeting hyperoxaluria.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

STAT-Diagnostica is a company dedicated to the development of near-patient testing products aimed at enhancing healthcare delivery. It specializes in creating point-of-care diagnostic devices designed for rapid turnaround applications and critical care environments. The company's flagship product, DiagCORE, is a portable multi-analyte instrument that supports both molecular and immunoassay testing across various clinical settings. By integrating multiple testing techniques into a single device, STAT-Diagnostica enables healthcare professionals to streamline patient care and improve diagnostic efficiency.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Asarina Pharma AB is a Swedish biotechnology company dedicated to developing innovative treatments for premenstrual dysphoric disorder (PMDD) and other conditions related to hormonal fluctuations. The company's primary focus is on Sepranolone, a therapeutic agent designed to address the challenges associated with PMDD. In addition to Sepranolone, Asarina is advancing a second-generation oral compound in preclinical development aimed at PMDD. The company's research is rooted in over 40 years of studies on Allopregnanolone-related neurological disorders, and it is also working on a new family of compounds known as GAMSA (GABA-A Modulating Steroid Antagonists). These efforts aim to create effective and safe treatments for various neuroendocrinological conditions that remain inadequately addressed in the current medical landscape.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Nuevocor is a preclinical-stage biopharmaceutical company dedicated to developing gene therapy-based treatments aimed at restoring cardiac function in hearts affected by disease. The company specializes in addressing genetic cardiomyopathies, which are characterized by abnormal mechanobiology. By focusing on modulating mechanical force transduction, Nuevocor seeks to provide innovative solutions that enable healthcare professionals to improve cardiac function in patients suffering from these conditions.